Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
about
Chemotherapy-and cancer-related nausea and vomitingManagement of chemotherapy-induced nausea and vomiting by risk profile: role of netupitant/palonosetronPalonosetron in the prevention of chemotherapy-induced nausea and vomiting: an evidence-based review of safety, efficacy, and place in therapyA Review of NEPA, a Novel Fixed Antiemetic Combination with the Potential for Enhancing Guideline Adherence and Improving Control of Chemotherapy-Induced Nausea and VomitingNeurokinin-1 receptor antagonists in preventing postoperative nausea and vomiting: a systematic review and meta-analysisRecent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive reviewDifference in the emetic control among highly emetogenic chemotherapy regimens: Implementation for appropriate use of aprepitantFosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomitingHighly frequent and enhanced injection site reaction induced by peripheral venous injection of fosaprepitant in anthracycline-treated patientsAPF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide-based highly emetogenic chemotherapy regimens: a post hoc subgroFilling in the gaps: reporting of concurrent supportive care therapies in breast cancer chemotherapy trials.A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy.The Role of Supportive Therapy in the Era of Modern Adjuvant Treatment - Current and Future Tools.Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference.Palonosetron in the management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day chemotherapy.Fosaprepitant and aprepitant: an update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomitingManagement of chemotherapy-induced nausea and vomiting : focus on newer agents and new uses for older agents.Neuropharmacology and management of chemotherapy-induced nausea and vomiting in patients with breast cancer.Use of granisetron transdermal system in the prevention of chemotherapy-induced nausea and vomiting: a reviewAprepitant: the evidence for its place in the prevention of chemotherapy-induced nausea and vomiting.Rolapitant for the treatment of chemotherapy-induced nausea and vomiting: a review of the clinical evidence.An update on palonosetron hydrochloride for the treatment of radio/chemotherapy-induced nausea and vomiting.Aprepitant and granisetron for the prophylaxis of radiotherapy-induced nausea and vomiting after moderately emetogenic radiotherapy for bone metastases: a prospective pilot studyProfile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV)Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasoneCasopitant: a novel NK(1)-receptor antagonist in the prevention of chemotherapy-induced nausea and vomiting.Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial.5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial.Pharmacokinetic evaluation of fosaprepitant dimegluminePharmacokinetics of aprepitant and dexamethasone after administration of chemotherapeutic agents and effects of plasma substance P concentration on chemotherapy-induced nausea and vomiting in Japanese cancer patients.Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo ItalAprepitant and fosaprepitant: a 10-year review of efficacy and safetyChemotherapy-Induced Nausea and Vomiting: Time for More Emphasis on Nausea?Prevalence of Delayed Nausea and/or Vomiting in Patients Treated With Oxaliplatin-Based Regimens for Colorectal CancerPrevention of delayed nausea: a University of Rochester Cancer Center Community Clinical Oncology Program study of patients receiving chemotherapy.Pharmaceutical care for patients with breast and ovarian cancerClinical practice guidelines on antiemetics in oncology.Antiemetic efficacy of single-dose palonosetron and dexamethasone in patients receiving multiple cycles of multiple day-based chemotherapyEffect of increase in duration of aprepitant consumption from 3 to 6 days on the prevention of nausea and vomiting in women receiving combination of anthracycline/cyclophosphamide chemotherapy: A randomized, crossover, clinical trial.Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial.
P2860
Q24644831-D9A38B4A-1A67-46E0-B9F4-2C1D0BD0966BQ26746211-23C918CA-046F-4BD6-9F7E-DEF055905FA7Q26783229-4C8D02F7-0206-4EE5-BE2E-CDDDFF782DC5Q26784064-28DDF92E-94ED-48C9-9E6E-8C9556CD4DE7Q26997344-58BBF9F7-9649-4DB7-B546-328B7C863660Q28081186-218EC2A3-3477-471E-B6CD-F837AD82953DQ28236344-744E5896-48AF-4478-A8D6-3E9307579E64Q28258863-059A2DE8-65CB-4A7E-8ACD-A8D5CFEF0B5AQ33556570-E58B0261-848D-4734-93B7-D975F6B8B9EAQ33734386-AD5C23E2-0463-4EFD-803D-B2712EF2B581Q33785011-68AD7579-DFF8-43F1-AA0B-AACD7F433FACQ33809590-8FD27DD9-4A0D-426F-A511-AF379C883E9EQ34095827-0822D863-0899-444E-B9B1-6723911E5F40Q34121232-9A3DAD7E-85E7-4975-8CE9-CDD67B3713AFQ34166946-B622C7D0-D6F1-44AB-BB60-F843A91E0CA6Q34239808-0A97E213-35E8-45F8-A0A8-653047DD69C6Q34327488-7DC732C7-9800-4B8A-9E28-7DBC591C6159Q34403552-F599CCE5-5C2A-49DF-B003-325955C6B6FDQ34417851-A9F1C810-B1C2-4F1D-9275-7F3D7CEAC1ADQ34450534-5C058A1D-D117-414D-BBBD-94B4C33BA387Q34512212-A4135F9C-63A1-484D-80EE-209F7F57FBB2Q34588516-C86ADA5D-ABE8-4DF6-B3E6-7E3FF065F833Q34637875-047A7253-75C6-4493-AB6B-8B1C7151DA73Q34775395-F1DC636C-B8F4-4413-840A-659C5880746AQ34941162-00FA44C9-AE08-4092-A4FA-0251C6E4C9F9Q34987555-4437A19C-539D-441E-8F48-707B2C3E7716Q35082647-73B006B3-D221-4E51-AEC9-B83D1D9873BBQ35146420-6D7C73B1-161B-4794-9BEB-CE2FD6950710Q35163168-5463E21B-E1EA-4979-A254-A58B1E296324Q35182204-5534769F-27DD-4E8E-94F5-74D0C7E34F19Q35195231-7E1BF271-0DE2-4D7D-ABE7-0CA58A29EB7DQ35345557-4E4B3909-99BB-442D-B916-04DE0AB61B0BQ36064834-40A83AA8-DC80-4BB7-B28B-CE55D39C23BEQ36095132-9051BC03-AECB-452B-9864-E3135810C399Q36222937-46AEB2EA-C176-4EDE-A268-46150C24C4B0Q36288172-061AA430-ADBB-4943-BE16-A1AF34E7EB08Q36334870-CC1194AF-C778-41BE-B2D0-CC26AEBD116BQ36345449-D3F4617E-7805-4A25-828F-5B84ED1916D8Q36357739-044A3969-3557-4403-A96F-291BFA5C301BQ36384479-8AC1D7A9-F394-4801-A8FE-0179D070A6DD
P2860
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Efficacy and tolerability of a ...... ately emetogenic chemotherapy.
@en
Efficacy and tolerability of a ...... ately emetogenic chemotherapy.
@nl
type
label
Efficacy and tolerability of a ...... ately emetogenic chemotherapy.
@en
Efficacy and tolerability of a ...... ately emetogenic chemotherapy.
@nl
prefLabel
Efficacy and tolerability of a ...... ately emetogenic chemotherapy.
@en
Efficacy and tolerability of a ...... ately emetogenic chemotherapy.
@nl
P2093
P356
P1476
Efficacy and tolerability of a ...... ately emetogenic chemotherapy.
@en
P2093
Carolyn M Hustad
David G Warr
Franck Skobieranda
George Klinger
Harry Raftopoulos
Hyman B Muss
Jørn Herrstedt
Munir Gabriel
Norman Bohidar
Paul J Hesketh
P304
P356
10.1200/JCO.2005.09.050
P407
P577
2005-04-01T00:00:00Z